Search

everythinglearnresearchcommunity

for

Search:↓

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

Minoxidil's effectiveness varies due to differences in sulfotransferase enzyme levels in the scalp, affecting people with conditions like ASD, liver disease, and androgenic alopecia. Treatments like topical tretinoin, microneedling, and using minoxidil sulfate instead of regular minoxidil can improve results for those with low enzyme levels.

The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.

A user is concerned about male pattern baldness despite their father having hair. Replies suggest visiting a dermatologist and considering finasteride or dutasteride, as natural methods are ineffective.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

The conversation is about someone being prescribed Dutasteride for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user is experiencing hair loss, initially diagnosed as Telogen Effluvium due to stress, but is concerned it might be Androgenetic Alopecia (AGA). A suggestion was made to consider using Minoxidil or Finasteride if the condition worsens.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The user is considering adding Alfatradiol or Pyralutamide to their current hair loss treatment of oral Dutasteride and Minoxidil. They are seeking advice on experiences and purchasing options for these products in the US.

A user switched from finasteride to dutasteride and from topical to oral minoxidil, experiencing significant hair shedding. They plan to continue this regimen for a year before deciding on any changes.

The user switched from finasteride and topical minoxidil to dutasteride and oral minoxidil due to lack of results. They are hopeful about dutasteride but are prepared to stop all medication if it doesn't work, as they have aggressive hair loss genetics.

19-year-old with Lichen Planopilaris tried various treatments unsuccessfully. Now considering hair systems, seeking experiences and opinions.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

The conversation is about hair loss treatments, specifically discussing the use of dutasteride, minoxidil, and the potential benefits of a DNA test and PRP therapy. Opinions vary, with some users skeptical about the DNA test and PRP, suggesting sticking with current treatments.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.

The dermatologist prescribed topical finasteride and minoxidil, but only finasteride is available in pill form. The user plans a telehealth visit to discuss options.

A 26-year-old is experiencing hair thinning and has received conflicting diagnoses of androgenetic alopecia and telogen effluvium. They are considering treatments like dutasteride, oral and topical minoxidil, and are unsure whether to start treatment or pursue further diagnosis like a scalp biopsy.

A user shared their 7-month progress using 1mg daily Dutasteride and 2.5-5mg daily oral Minoxidil for diffuse unpatterned alopecia, showing significant hair regrowth with reduced shedding and no side effects. They experienced a severe initial shed but now have visual improvement, despite hair still being thinner than before.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

The user experienced worsening hair loss despite using dutasteride tablets and is considering switching to dutasteride gel capsules due to concerns about tablet bioavailability. Another user mentioned that countries like Japan, Korea, and India use the tablet form, suggesting the form may not be the issue.

Increasing the sult1a1 enzyme on the scalp may improve response to topical minoxidil. The user suggests using a baking soda solution, DMSO, and tretinoin to enhance enzyme activity and minoxidil effectiveness.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

Hair loss itch is caused by DHT attacking follicles and stimulating nerves. Finasteride users who respond well don't experience this itch.

Exploring the potential of latanoprost as a hair loss treatment in combination with minoxidil and finasteride.

The conversation is about finding a source to buy topical dutasteride for hair loss treatment, as it is out of stock at Minoxidil Express. The discussion focuses on alternative purchasing options.